June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Antibiotic Resistance Surveillance of Ocular Pathogens - four years of ARMOR Study Results
Author Affiliations & Notes
  • Wolfgang Haas
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Jennifer Deane
    Eurofins Medinet, Inc., Chantilly, NY
  • Timothy Morris
    Microbiology and Sterilization Sciences, Bausch & Lomb, Inc, Rochester, NY
  • Daniel Sahm
    Eurofins Medinet, Inc., Chantilly, NY
  • Footnotes
    Commercial Relationships Wolfgang Haas, Bausch & Lomb, Inc. (E); Jennifer Deane, None; Timothy Morris, Bausch & Lomb, Inc. (E); Daniel Sahm, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2904. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wolfgang Haas, Jennifer Deane, Timothy Morris, Daniel Sahm; Antibiotic Resistance Surveillance of Ocular Pathogens - four years of ARMOR Study Results. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2904.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Antibiotic resistance surveillance data can guide clinicians in the empiric treatment of ocular infections. Here we report the study results to date for the 2012 ARMOR (Antibiotic Resistance Monitoring in Ocular MicRoorganisms) surveillance study and compare the results to those from the previous three years.

Methods: To date, 456 isolates of Streptococcus pneumoniae, Staphylococcus aureus, coagulase-negative staphylococci (CoNS), Pseudomonas aeruginosa, and Haemophilus influenzae from 25 sites were subjected to antibiotic susceptibility testing. Minimum inhibitory concentrations were determined by broth microdilution for up to 16 representative antibiotics per Clinical and Laboratory Standards Institute methods. Systemic breakpoints (where available) were used to categorized isolates as susceptible or non-susceptible (intermediate and resistant).

Results: While drug resistance among H. influenzae isolates was not observed, non-susceptibility among P. aeruginosa isolates was noted for ciprofloxacin (9.1%), imipenem (11.4%), tobramycin (4.5%), and polymyxin B (4.5%). S. pneumoniae isolates were non-susceptible to imipenem (13.1%), penicillin (4.9%), chloramphenicol (3.3%), and azithromycin (41.0%). S. aureus and CoNS isolates were non-susceptible to oxacillin/methicillin (37.3-41.9%), ciprofloxacin (33.8-36.6%), clindamycin (18.3-31.3%), azithromycin (58.8-60.1%), and other antibiotics. More than 33% of S. aureus and CoNS isolates were resistant to 3 or more antibiotics. Methicillin-resistant isolates of S. aureus (MRSA) and CoNS (MRCoNS) were predominantly multi-drug resistant (>73%). Compared to the three previous years, non-susceptibility rates were similar and the new data set reduced some of the fluctuation seen over the previous years.

Conclusions: After accounting for annual fluctuations, overall resistance rates generally did not show substantial changes over the four year study period. However, a number of isolates were resistant to commonly used ophthalmic antibiotics. Multi-drug resistance was especially prevalent among the MRSA and MRCoNS isolates. Therefore, continued vigilance is warranted to monitor the contribution of resistant isolates to the pathogen population.

Keywords: 463 clinical (human) or epidemiologic studies: prevalence/incidence • 433 bacterial disease • 422 antibiotics/antifungals/antiparasitics  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.